Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...
LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...
According to the province's respiratory illness surveillance report COVID-19 test positivity continues to decline. Influenza ...
For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...
Cases of influenza continue to soar across Canada, meanwhile rates of respiratory syncytial virus, or RSV, and COVID-19 are ...
Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.
A data point is marked as “insufficient data” if wastewater samples test negative for a virus (because levels are too low to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback